Data Insights

Daratumumab by Johnson & Johnson for Lymphoblastic Lymphoma: Likelihood of Approval

Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for Lymphoblastic Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Daratumumab in Lymphoblastic Lymphoma

Data Insights

Daratumumab by Johnson & Johnson for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval

Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute...

Likelihood of Approval and Phase Transition Success Rate Model - Daratumumab in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)

Data Insights

Daratumumab by Johnson & Johnson for Lupus Nephritis: Likelihood of Approval

Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for Lupus Nephritis. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Daratumumab in Lupus Nephritis

Data Insights

Daratumumab by Johnson & Johnson for Antiphospholipid Syndrome: Likelihood of Approval

Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for Antiphospholipid Syndrome. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Daratumumab in Antiphospholipid Syndrome

Data Insights

Daratumumab by Johnson & Johnson for Systemic Lupus Erythematosus: Likelihood of Approval

Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for Systemic Lupus Erythematosus. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Daratumumab in Systemic Lupus Erythematosus

Data Insights

Daratumumab by Johnson & Johnson for Lymphoma: Likelihood of Approval

Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for Lymphoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Daratumumab in Lymphoma

Data Insights

Daratumumab by Johnson & Johnson for Primary Systemic Amyloidosis: Likelihood of Approval

Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for Primary Systemic Amyloidosis. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Daratumumab in Primary Systemic Amyloidosis

Data Insights

Daratumumab by Johnson & Johnson for T-Cell Leukemia: Likelihood of Approval

Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for T-Cell Leukemia. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Daratumumab in T-Cell Leukemia

Data Insights

Daratumumab by Johnson & Johnson for Precursor B-Cell Lymphoblastic Leukemia-Lymphoma: Likelihood of Approval

Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. According...

Likelihood of Approval and Phase Transition Success Rate Model - Daratumumab in Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Data Insights

Daratumumab by Johnson & Johnson for POEMS Syndrome (Crow-Fukase Syndrome): Likelihood of Approval

Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for POEMS Syndrome (Crow-Fukase Syndrome). According...

Likelihood of Approval and Phase Transition Success Rate Model - Daratumumab in POEMS Syndrome (Crow-Fukase Syndrome)

Data Insights

Daratumumab by Johnson & Johnson for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

Daratumumab is under clinical development by Johnson & Johnson and currently in Phase I for Chronic Lymphocytic Leukemia (CLL). According...

Likelihood of Approval and Phase Transition Success Rate Model - Daratumumab in Chronic Lymphocytic Leukemia (CLL)

Data Insights

Daratumumab by Johnson & Johnson for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL)....

Likelihood of Approval and Phase Transition Success Rate Model - Daratumumab in Refractory Chronic Lymphocytic Leukemia (CLL)

Data Insights

Daratumumab by Johnson & Johnson for Pancreatic Cancer: Likelihood of Approval

Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for Pancreatic Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Daratumumab in Pancreatic Cancer

Data Insights

Daratumumab by Johnson & Johnson for T-Cell Lymphomas: Likelihood of Approval

Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for T-Cell Lymphomas. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Daratumumab in T-Cell Lymphomas

Data Insights

Daratumumab by Johnson & Johnson for Non-Small Cell Lung Cancer: Likelihood of Approval

Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for Non-Small Cell Lung Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - Daratumumab in Non-Small Cell Lung Cancer

Data Insights

Daratumumab by Johnson & Johnson for Lupus Nephritis: Likelihood of Approval

Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for Lupus Nephritis. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Daratumumab in Lupus Nephritis

Data Insights

Daratumumab by Johnson & Johnson for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval

Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Daratumumab in Pancreatic Ductal Adenocarcinoma

Data Insights

Daratumumab by Johnson & Johnson for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According...

Likelihood of Approval and Phase Transition Success Rate Model - Daratumumab in Triple-Negative Breast Cancer (TNBC)

Data Insights

Daratumumab by Johnson & Johnson for Natural Killer Cell Lymphomas: Likelihood of Approval

Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for Natural Killer Cell Lymphomas. According...

Likelihood of Approval and Phase Transition Success Rate Model - Daratumumab in Natural Killer Cell Lymphomas

Data Insights

Daratumumab by Johnson & Johnson for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy: Likelihood of Approval

Daratumumab is under clinical development by Johnson & Johnson and currently in Phase II for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy....

Likelihood of Approval and Phase Transition Success Rate Model - Daratumumab in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy